Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test could spare bile duct cancer patients unnecessary surgery

NCT ID NCT06381648

Diagnosis Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new blood test called LyMIC that looks for tiny particles (exosomes) released by cancer cells. The goal was to see if it could accurately tell whether bile duct cancer has spread to nearby lymph nodes before surgery. Researchers analyzed blood samples from 230 patients with intrahepatic cholangiocarcinoma. If successful, this test could help doctors choose the right treatment—like whether to remove lymph nodes—without needing invasive procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LyMIC (a panel of exosomal miRNAs measured in blood)
What this could lead to
If this blood test proves accurate, it could help doctors decide on the best treatment approach for intrahepatic cholangiocarcinoma without needing invasive surgery to check lymph nodes.
What could go wrong
This is a completed study, but the test's accuracy is still being evaluated. It may not be reliable enough for routine use, and further validation in larger, diverse groups is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

230 people

The number who actually took part.

Started

Apr 2023

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Individuals who were diagnosed with Intrahepatic cholangiocarcinoma

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * A histologically confirmed diagnosis of intrahepatic cholangiocarcinoma. * Received standard diagnostic and staging procedures as per local guidelines * Availability of at least one blood-derived sample, drawn before receiving any curative-intent treatment Exclusion Criteria: * Lack of or inability to provide informed consent * Synchronous Intrahepatic cholangiocarcinoma and non- Intrahepatic cholangiocarcinoma diagnosed at or before surgery * Secondary liver cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cholangiocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma intrahepatic cholangiocarcinoma Lymphatic Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cholangiocarcinoma Cholangiocarcinoma resectable Cholangiocarcinoma, intrahepatic Cholangiocarcinoma; liver

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91016, United States

  • Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University

    Hokkaido, Sapporo, 060-8648, Japan

  • Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University

    Fukuoka, 812-8582, Japan

  • Department of Surgery, Tokushima University

    Tokushima, 770-8503, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.